Tara M Brinkman1, Johnnie K Bass2, Zhenghong Li1, Kirsten K Ness1, Amar Gajjar3, Alberto S Pappo3, Gregory T Armstrong1,3, Thomas E Merchant4, Deo Kumar Srivastava5, Leslie L Robison1, Melissa M Hudson1,3, James G Gurney1,6. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Rehabilitation Services, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. School of Public Health, University of Memphis, Tennessee.
Abstract
BACKGROUND: Survivors of childhood cancer who are treated with platinum-based chemotherapy and/or cranial radiation are at risk of treatment-induced hearing loss. However, the effects of such hearing loss on adult social attainment have not been well elucidated. METHODS: Adult survivors of pediatric central nervous system (CNS) solid tumors (180 survivors) and non-CNS solid tumors (226 survivors) who were treated with potentially ototoxic cancer therapy completed audiologic evaluations and questionnaires assessing their perception of social functioning and social attainment (ie, independent living, marriage, and employment). Audiograms were graded with the Chang ototoxicity grading scale. Analyses were stratified by tumor type (ie, CNS vs non-CNS). Multivariable logistic regression models were conducted with adjustment for age; sex; chronic health conditions; and, for the CNS group, IQ. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were reported. RESULTS: Serious hearing loss (that requiring a hearing aid or deafness) was detected in 36% of survivors of CNS tumors and 39% of survivors of non-CNS tumors. Serious hearing loss was associated with an increased risk of perceived negative impact in ≥1 areas of social functioning (survivors of non-CNS tumors: OR, 1.83 [95% CI, 1.00-3.34]). Among survivors of non-CNS tumors, serious hearing loss was associated with 2-fold increased risk of nonindependent living (OR, 2.19; 95% CI, 1.19-4.04) and unemployment or not graduating from high school (OR, 1.85; 95% CI, 1.00-3.34). CONCLUSIONS: A substantial proportion of adult survivors of childhood cancer treated with potentially ototoxic therapy have serious hearing loss. Treatment-induced hearing loss was found to be associated with reduced social attainment, both perceived and actual, in this study sample.
BACKGROUND: Survivors of childhood cancer who are treated with platinum-based chemotherapy and/or cranial radiation are at risk of treatment-induced hearing loss. However, the effects of such hearing loss on adult social attainment have not been well elucidated. METHODS: Adult survivors of pediatric central nervous system (CNS) solid tumors (180 survivors) and non-CNS solid tumors (226 survivors) who were treated with potentially ototoxic cancer therapy completed audiologic evaluations and questionnaires assessing their perception of social functioning and social attainment (ie, independent living, marriage, and employment). Audiograms were graded with the Chang ototoxicity grading scale. Analyses were stratified by tumor type (ie, CNS vs non-CNS). Multivariable logistic regression models were conducted with adjustment for age; sex; chronic health conditions; and, for the CNS group, IQ. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were reported. RESULTS: Serious hearing loss (that requiring a hearing aid or deafness) was detected in 36% of survivors of CNS tumors and 39% of survivors of non-CNS tumors. Serious hearing loss was associated with an increased risk of perceived negative impact in ≥1 areas of social functioning (survivors of non-CNS tumors: OR, 1.83 [95% CI, 1.00-3.34]). Among survivors of non-CNS tumors, serious hearing loss was associated with 2-fold increased risk of nonindependent living (OR, 2.19; 95% CI, 1.19-4.04) and unemployment or not graduating from high school (OR, 1.85; 95% CI, 1.00-3.34). CONCLUSIONS: A substantial proportion of adult survivors of childhood cancer treated with potentially ototoxic therapy have serious hearing loss. Treatment-induced hearing loss was found to be associated with reduced social attainment, both perceived and actual, in this study sample.
Authors: James G Gurney; Johnnie K Bass; Arzu Onar-Thomas; Jie Huang; Murali Chintagumpala; Eric Bouffet; Tim Hassall; Sridharan Gururangan; John A Heath; Stewart Kellie; Richard Cohn; Michael J Fisher; Atmaram Pai Panandiker; Thomas E Merchant; Ashok Srinivasan; Cynthia Wetmore; Ibrahim Qaddoumi; Clinton F Stewart; Gregory T Armstrong; Alberto Broniscer; Amar Gajjar Journal: Neuro Oncol Date: 2014-01-10 Impact factor: 12.300
Authors: Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin Journal: J Natl Cancer Inst Date: 2002-01-02 Impact factor: 13.506
Authors: V G Schweitzer; J E Hawkins; D J Lilly; C J Litterst; G Abrams; J A Davis; M Christy Journal: Otolaryngol Head Neck Surg Date: 1984-02 Impact factor: 3.497
Authors: Johnnie K Bass; Kristin R Knight; Torunn I Yock; Kay W Chang; Douglas Cipkala; Satkiran S Grewal Journal: Pediatr Blood Cancer Date: 2016-02-29 Impact factor: 3.167
Authors: Tara M Brinkman; Chenghong Li; Kathryn Vannatta; Jordan G Marchak; Jin-Shei Lai; Pinki K Prasad; Cara Kimberg; Stefanie Vuotto; Chongzhi Di; Deokumar Srivastava; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: Victoria W Willard; James L Klosky; Chenghong Li; Deo Kumar Srivastava; Tara M Brinkman; Leslie L Robison; Melissa M Hudson; Sean Phipps Journal: Cancer Date: 2017-01-18 Impact factor: 6.860
Authors: Johnnie K Bass; Wei Liu; Pia Banerjee; Tara M Brinkman; Daniel A Mulrooney; Amar Gajjar; Alberto S Pappo; Thomas E Merchant; Gregory T Armstrong; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Tara M Brinkman; Christopher J Recklitis; Gisela Michel; Martha A Grootenhuis; James L Klosky Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Amber Khan; Nidha Mubdi; Amy Budnick; Darren R Feldman; Sharon W Williams; Seema Patel; Emily S Tonorezos Journal: Cancer Date: 2020-01-03 Impact factor: 6.860